RDT

Molecular Partners Reports Corporate Highlights From Q4 2023 and Key Financials for Full Year 2023

Retrieved on: 
Thursday, March 14, 2024
CD33, GSK, Patient, Macrophage, Society, CD3, CD47, DLL3, Therapy, Molecular Partners, TME, Partner, DRS, ASH, AML, SNMMI, Partnership, RDT, Radionuclide, Tetra, Novartis, HSCT, MHS, FTE, Exposition, Delta, Safety, SITC, Amgen, Hematopoietic stem cell transplantation, FAP, Disease, Nuclear medicine, Immunotherapy, District court, Neoplasm, EANM, Alpha particle, JNJ, Tumor microenvironment, Gene family, CD70, AACR, CD40, CHF, CD123, NK, Engineering, Antigen, Molecule, Annual general meeting, Toxicity, CD16, B cell, Conference, MBA, DARPin, Data, Molecular imaging, Pharmaceutical industry

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 14, 2024 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced its corporate highlights and audited financial results for the full year 2023.

Key Points: 
  • 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced its corporate highlights and audited financial results for the full year 2023.
  • “2023 was a year of successful innovation and execution on our strategy, focusing on novel mechanisms that we believe only DARPin therapies can deliver.
  • In addition to the above updates, Molecular Partners continued to progress its RDT portfolio of projects in partnership with Novartis.
  • In the financial year 2023, Molecular Partners recognized total revenues and other income of CHF 7.0 million (2022: CHF 189.6 million) and incurred total expenses of CHF 68.1 million (2022: CHF 73.0 million).

Antibody Solutions Secures Grant for Challenging Diagnostic Initiative

Retrieved on: 
Thursday, April 4, 2024
Science, Biotechnology, Research, Pharmaceutical, Health, Medical Devices, Infectious Diseases, Genetics, LDH, Infection, Bill, RDT, Risk, Public, NGS, Antibody Solutions, Doctor of Philosophy, LMIC, Biology, Malaria, Antibody, Melinda French Gates, Vaccine

Antibody Solutions, a leading provider of fit-for-purpose antibody discovery services, announced today that it received a 15-month grant for nearly $1.2 million from the Bill & Melinda Gates Foundation to develop reagents for highly-specified rapid diagnostic tests (RDT) to detect malaria.

Key Points: 
  • Antibody Solutions, a leading provider of fit-for-purpose antibody discovery services, announced today that it received a 15-month grant for nearly $1.2 million from the Bill & Melinda Gates Foundation to develop reagents for highly-specified rapid diagnostic tests (RDT) to detect malaria.
  • The end result is that those RDTs are unable to differentiate between different strains of malaria,” explained John Kenney, PhD, co-founder and president of Antibody Solutions.
  • ”
    Antibody Solutions has already begun work to identify these new antibody reagents by harnessing Cellestive, its antibody discovery platform, that includes multiple discovery pathways such as hybridoma library, primary B-cell screening, and guided next-generation sequencing (NGS).
  • The grant from the foundation will also allow Antibody Solutions to work with industry experts in both public health and the development and deployment of healthcare solutions in low- and middle-income (LMIC) settings, ensuring that these reagents will be widely available.

United States DoD Artificial Intelligence (AI) Research 2024: Growth Opportunities and Key Contractors - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 21, 2024
Technology, Artificial Intelligence, Defense, Government Technology, Ecosystem, RDT, Research, Artificial intelligence, AI, Traction

The "United States Department of Defense (DoD) Artificial Intelligence (AI) Growth Opportunities" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "United States Department of Defense (DoD) Artificial Intelligence (AI) Growth Opportunities" report has been added to ResearchAndMarkets.com's offering.
  • The defense sector is keenly focused on Artificial Intelligence (AI) as a pivotal component of its technological advancement strategy.
  • A recently published study has now become available that thoroughly examines the contracting landscape within the United States Department of Defense (DoD) in relation to AI.
  • The insights gleaned will be instrumental for companies aiming to capture opportunities within the dynamic and forward-focused field of defense AI.

Amentum Awarded $245 Million IAC MAC Contract to Deliver Microelectronics Capabilities for the U.S. Navy

Retrieved on: 
Monday, March 11, 2024
Research, Other Defense, Contracts, Technology, Defense, Semiconductor, Science, Government Technology, Engineering, Other Technology, Manufacturing, Military, Surge (drink), GXM, Radiation, DTIC, Weapon, RDT, Naval Surface Warfare Center, IDEA, Laboratory, NSWC, Defense Technical Information Center, Ecosystem, SSP, Navy, 3D printing

The contract will strengthen our nation’s deterrence and defense by delivering state-of-the-art services and independent data driven solutions and establishing GXM as the national leader in high-reliability, radiation hardened microelectronics.

Key Points: 
  • The contract will strengthen our nation’s deterrence and defense by delivering state-of-the-art services and independent data driven solutions and establishing GXM as the national leader in high-reliability, radiation hardened microelectronics.
  • “Amentum will leverage our digital engineering ecosystem and model-based system engineering expertise to enhance capabilities for strategic radiation hardened microelectronics," said Jill Bruning, President of Amentum’s Engineering, Science, and Technology Group.
  • This will include updating and enhancing related microelectronics T&E facilities and laboratories; related capabilities associated with the Navy’s Fleet Ballistic Missile system and Strategic Weapons System; and DoD strategic weapons platforms employing advanced and critical microelectronics technologies.
  • Amentum will also support the Navy by increasing prototyping and test surge capacity and providing radiation hardened and survivability subject matter expertise.

Reveal Technology, Inc. Receives $3.2M Award With U.S. Marine Corps Warfighting Laboratory (MCWL)

Retrieved on: 
Thursday, March 28, 2024
Aircraft, USMC, AeroVironment, Intelligence, Farstream, RDT, RAID, Applied Physics Laboratory, Research, Artificial intelligence, ISR, AI, Kinesis, MCWL, AV, Tomahawk

BOZEMAN, Mont., March 28, 2024 /PRNewswire/ -- Reveal Technology, Inc. (Reveal), is proud to share that they have been granted a $3.2M research, development, testing and evaluation (RDT&E) contract award with the Marine Corps Warfighting Laboratory (MCWL).

Key Points: 
  • BOZEMAN, Mont., March 28, 2024 /PRNewswire/ -- Reveal Technology, Inc. (Reveal), is proud to share that they have been granted a $3.2M research, development, testing and evaluation (RDT&E) contract award with the Marine Corps Warfighting Laboratory (MCWL).
  • In support of the overarching force design goals of investing in unmanned aircraft systems and applied artificial intelligence (AI), Reveal will provide integrated AI-enhanced ISR capabilities for Marine Corps experimentation via the Farsight application.
  • We're looking forward to working with our project stakeholders to revolutionize Marine Corp ISR using cutting-edge computer vision and AI," said Garrett Smith, CEO of Reveal.
  • "Reveal understands the importance of autonomous capabilities in the next fight and looks forward to seeing its impact on joint all-domain operations."

United States Department of Defense (DoD) Artificial Intelligence (AI) - Key Growth Opportunities in Artificial Intelligence for Operations Analysis and Predictive Analytics

Retrieved on: 
Wednesday, March 20, 2024
RDT, Outline, Calendar, Organization, Research, Artificial intelligence, Environment, AI, Arms industry

DUBLIN, March 20, 2024 /PRNewswire/ -- The "United States Department of Defense (DoD) Artificial Intelligence (AI) Growth Opportunities" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, March 20, 2024 /PRNewswire/ -- The "United States Department of Defense (DoD) Artificial Intelligence (AI) Growth Opportunities" report has been added to ResearchAndMarkets.com's offering.
  • This research service focuses on the United States (US) Department of Defense (DoD) artificial intelligence (AI) contracting information for research, development, test, and evaluation (RDT&E); procurement; and services.
  • The analyst has segmented contracting data by military department and overall leading firms.
  • The main goals are to understand the current state of the DoD AI competitive environment and point out both high-spending areas and opportunities to participate in the DoD AI market.

Kratos Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Tuesday, February 13, 2024
Weapon, Radar, Investment, Growth, Sale, RDT, KUS, Probability, Software, Unitary state, Research and development, Defense, KGS, S&T, Communications satellite, GAAP, STS, Pedigree, EPS, TT&C, Total, Forecasting, National security, Valkyrie, Adjustment, Capital expenditure, Public expenditure, Capital, CRA, Acquisition, Hypersonic speed, Technology company, Revenue, Consolidated, Video game

Adjusted earnings per share (EPS) was $0.12 for the fourth quarter of 2023, compared to $0.08 for the fourth quarter of 2022.

Key Points: 
  • Adjusted earnings per share (EPS) was $0.12 for the fourth quarter of 2023, compared to $0.08 for the fourth quarter of 2022.
  • Fourth quarter 2023 Revenues of $273.8 million increased $24.5 million, reflecting 9.8 percent and 7.3 percent organic growth, respectively, from fourth quarter 2022 Revenues of $249.3 million.
  • KUS’s Operating Income was $1.0 million in the fourth quarter of 2023 compared to $1.8 million in the fourth quarter of 2022.
  • KUS’s Adjusted EBITDA for the fourth quarter of 2023 was $4.0 million, compared to fourth quarter 2022 KUS Adjusted EBITDA of $4.5 million, reflecting reduced volume.

MANGORX AWARDS SAN FRANCISCO TEAM FREE MANGORX ED PRODUCTS FOR ONE YEAR FOLLOWING BIG GAME LOSS TO KANSAS CITY

Retrieved on: 
Tuesday, February 13, 2024
RDT, Entrepreneurship, Sildenafil, SF, Arginine, Oxytocin, Music

Dallas, Texas, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (Nasdaq: MGRX) (“MangoRx” or the “Company”), a men’s health & wellness company, will offer a free one-year supply of its “Mango” erectile dysfunction product to the San Francisco players and coaches to raise spirits following Sunday’s Big Game loss, ensuring they can still perform in the bedroom after losing on the field.

Key Points: 
  • Players and coaches of the SF-based team can send redemption inquiries to [email protected] with subject line “The Big Game” for access to their one-year supply of Mango.
  • MangoRx’s Tadalafil and Sildenafil based Mango ED products are compounded with both Oxytocin and L-Arginine in a tasty Mango-flavored, rapid dissolve tablet (RDT).
  • “With a defeating loss, the disappointment can linger into the bedroom but we want to make sure San Francisco players and fans can still score after the game.
  • At MangoRx, we want to help take the pressure off and focus on good times ahead,” says Jacob Cohen, Co-Founder and CEO of MangoRx.

MANGORX TO OFFER THE BIG GAME’S LOSING TEAM A FREE ONE YEAR SUPPLY OF ITS ED PRODUCT, MANGO, TO HELP RAISE… SPIRITS

Retrieved on: 
Tuesday, February 6, 2024
Life, Arginine, Erectile dysfunction, Sadness, Oxytocin, Running, Sildenafil, Marketing, Radio, Entrepreneurship, Depression, Bedroom, Stage fright, Sport, RDT, Nursing

Dallas, Texas, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (Nasdaq: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men’s health and wellness products via a secure telemedicine platform, including its uniquely formulated hair growth product (“GROW”) and erectile dysfunction (“ED”) drug (“Mango”), announces that regardless of who loses the Big Game this Sunday, they are prepared to offer a free one-year supply of its Mango ED products for the entire losing team, ensuring they still get sacked after the game.

Key Points: 
  • This code will be available to fans following the results of the Big Game.
  • MangoRx’s signature ED product Mango (think "Man, Go) is a uniquely formulated drug which leverages the active ingredients found in either Cialis™ (Tadalafil) or Viagra™ (Sildenafil).
  • MangoRx’s Tadalafil and Sildenafil based Mango ED products are compounded with both Oxytocin and L-Arginine in a tasty Mango-flavored, rapid dissolve tablet (RDT).
  • “Just because your team doesn’t perform on the field, doesn’t mean the fans shouldn’t be able to score.

TSS Solutions Appoints Gary Ambrose as COO

Retrieved on: 
Wednesday, January 31, 2024
Technology, Other Defense, Engineering, Satellite, Telecommunications, Aerospace, Manufacturing, Government Technology, Defense, Multimedia, Lead, Electronics, Acorn, UAS, RADAR, AGC Aerospace & Defense, Freedom, Investment, Intelligence, Aviation, SATCOM, TSS, Navy, RDT, Woman, Risk management

View the full release here: https://www.businesswire.com/news/home/20240131551257/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240131551257/en/
    “Gary is bringing over three decades of aviation and defense expertise into TSS Solutions, and we welcome his leadership and drive to assist TSS with rapid technology insertions that add value to our existing RADAR portfolio,” says Don DiFrisco, TSS Solutions President and CEO.
  • TSS Solutions serves the global defense, telecommunications, and commercial industries.
  • The Company is committed to building innovative products and delivering world-class engineering and technical services to support customers' missions globally.
  • The men and women of TSS Solutions are proud to support the United States and its allies who protect national interests and preserve freedom and stability around the world.